Veradermics, a developer of an oral treatment for pattern hair loss, began trading on the New York Stock Exchange with shares ...
Veradermics is set to raise $200 million in an IPO to fund its novel extended-release oral minoxidil for pattern hair loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results